Mouse alpha-fetoprotein enhancer II fused to a human beta-globin minimal promoter (AFP/β-globin)
Chimeric liver promoter combining an enhancer from the mouse alpha-fetoprotein (AFP) gene with a minimal human beta-globin promoter, reproducing the AFP gene's own developmental expression pattern - active in fetal liver, yolk sac, and fetal gut, silenced after birth, and reactivated during liver regeneration. Restricts transgene expression to fetal or regenerating hepatocytes rather than the quiescent adult liver.
Length: 2810 bp
Strength: moderate
Tissue: Fetal liver, yolk sac, and fetal gut; silenced in normal adult liver and reactivated during liver regeneration (Vacher and Tilghman, 1990; Jin et al. 2009)
Expression: developmental
Origin: Mouse Afp gene enhancer + human HBB minimal promoter
Characteristics
Fused to a heterologous human beta-globin promoter, the mouse AFP enhancer reproduces the AFP gene's own tissue pattern - yolk sac, fetal liver, and fetal gut - in transgenic mice (Ramesh et al. 1995). AFP transcription, and therefore expression driven by its enhancer, is silenced in normal adult liver by a dominant trans-acting repressor (Vacher and Tilghman, 1990) and is reactivated roughly 6-fold during chemically induced liver regeneration, an induction that requires the enhancer region (Jin et al. 2009).
Applications: Restricts transgene or reporter expression to fetal hepatocytes, the yolk sac, and fetal gut, or to regenerating adult liver, while remaining silent in the quiescent adult liver (Ramesh et al. 1995; Jin et al. 2009); used to study liver regeneration and hepatocyte proliferation as a fetal/regenerating-liver-selective alternative to constitutive liver promoters such as albumin or TBG.
Limitations: Inactive in normal, quiescent adult liver due to a dominant trans-acting repressor (Vacher and Tilghman, 1990), so it cannot be used where sustained expression in mature hepatocytes is required, unlike constitutive liver promoters such as Alb or TBG; expression instead depends on a fetal, regenerative, or injury state that reactivates AFP transcription (Jin et al. 2009).
